Local anesthetic interaction with human ether-a-go-go-related gene (HERG) channels: Role of aromatic amino acids Y652 and F656

Anesthesiology

Volumn 103, Issue 1, 2005, Pages 102-112

  Siebrands, Cornelia C ^a   Schmitt, Nicole ^c   Friederich, Patrick ^b  

^a Inst for Neural Signal Transduction   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BUPIVACAINE; LOCAL ANESTHETIC AGENT; MEPIVACAINE; POTASSIUM CHANNEL HERG; ROPIVACAINE;

ANIMAL CELL; ARTICLE; CHO CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; LIPOPHILICITY; NONHUMAN; PATCH CLAMP; PRIORITY JOURNAL; ROOM TEMPERATURE; STEREOCHEMISTRY;

EID: 21744445104     PISSN: 00033022     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000542-200507000-00017     Document Type: Article

References (36)

1. Sanguinetti MC, Jiang C, Curran ME, Kearing MT: A mechanistic link between an inherited and an acquired cardiac arrhythmia:HERG encodes the IKr potassium channel. Cell 1995; 81:299-307
2. Mitcheson JS, Chen J, Lin M, Culberson C, Sanguinetti MC: A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci U S A 2000; 97:12329-33
3. Spector PS, Curran ME, Keating MT, Sanguinetti MC: Class III antiarrhythmic drugs block HERG, a human cardiac delayed rectifier K+ channel: Open-channel block by methanesulfonanilides. Circ Res 1996; 78:499-503
4. Suessbrich H, Waldegger S, Lang F, Busch AE: Blockade of HERG channels expressed in Xenopus oocytes by the histamine receptor antagonists terfenadine and astemizole. FEBS Lett 1996; 385:77-80
5. Roy M, Dumaine R, Brown AM: HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine. Circulation 1996; 94:817-23
6. Rampe D, Murawsky MK, Grau J, Lewis EW: The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG. J Pharmacol Exp Ther 1998; 286:788-93
7. Rampe D, Roy ML, Dennis A, Brown AM: A mechanism for the proarrhythmic effects of cisapride (Propulsid): High affinity blockade of the human cardiac potassium channel HERG. FEBS Lett 1997; 417:28-32
8. Walker BD, Singleton CB, Bursill JA, Wyse KR, Valenzuela SM, Qiu MR, Breit SN, Campbell TJ: Inhibition of the human ether-a-go-go-related gene (HERG) potassium channel by cisapride: Affinity for open and inactivated states. Br J Pharmacol 1999; 128:444-50
9. Stanat SJ, Carlton CG, Crumb Jr, WJ Agrawal, KC, Clarkson CW: Characterization of the inhibitory effects of erythromycin and clarithromycin on the HERG potassium channel. Mol Cell Biochem 2003; 254:1-7
10. Lipka LJ, Jiang M, Tseng GN: Differential effects of bupivacaine on cardiac K channels: Role of channel inactivation and subunit composition in drug-channel interaction. J Cardiovasc Electrophysiol 1998; 9:727-42
11. Gonzalez T, Arias C, Caballero R, Moreno I, Delpon E, Tamargo J, Valenzuela C: Effects of levobupivacaine, ropivacaine and bupivacaine on HERG channels. Stereoselective bupivacaine block. Br J Pharmacol 2002; 137:1269-79
12. Friederich P, Solth A, Schillemeit S, Isbrandt D: Local anaesthetic sensitivities of cloned HERG channels from human heart: comparison with HERG/MiRP1 and HERG/MiRP1 T8A. Br J Anaesth 2004; 92:93-101
13. del Camino D, Holmgren M, Liu Y, Yellen G: Blocker protection in the pore of a voltage-gated K+ channel and its structural implications. Nature 2000; 403:321-5
14. Mitcheson JS, Chen J, Sanguinetti MC: Trapping of a methanesulfonanilide by closure of the HERG potassium channel activation gate. J Gen Physiol 2000; 115:229-40
15. Lees-Miller JP, Duan Y, Teng GQ, Duff HJ: Molecular determinant of high-affinity dofetilide binding to HERG1 expressed in Xenopus oocytes: Involvement of S6 sites. Mol Pharmacol 2000; 57:367-74
16. Fernandez D, Ghanta A, Kauffman GW, Sanguinetti MC: Physicochemical features of the HERG channel drug binding site. J Biol Chem 2004; 279:10120-7
17. Kamiya K, Mitcheson JS, Yasui K, Kodama I, Sanguinetti MC: Open channel block of HERG K(+) channels by vesnarinone. Mol Pharmacol 2001; 60: 244-53
18. Sanchez-Chapula JA, Navarro-Polanco RA, Culberson C, Chen J, Sanguinetti MC: Molecular determinants of voltage-dependent human ether-a-go-go related gene (HERG) K+ channel block. J Biol Chem 2002; 277:23587-95
19. Sanchez-Chapula JA, Ferrer T, Navarro-Polanco RA, Sanguinetti MC: Volt-age-dependent profile of human ether-a-go-go-related gene channel block is influenced by a single residue in the S6 transmembrane domain. Mol Pharmacol 2003; 63:1051-8
20. Milnes JT, Crociani O, Arcangeli A, Hancox JC, Witchel HJ: Blockade of HERG potassium currents by fluvoxamine: Incomplete attenuation by S6 mutations at F656 or Y652. Br J Pharmacol 2003; 139:887-98
21. Scholz EP, Zitron E, Kiesecker C, Lueck S, Kathofer S, Thomas D, Weretka S, Peth S, Kreye VA, Schoels W, Katus HA, Kiehn J, Karle CA: Drug binding to aromatic residues in the HERG channel pore cavity as possible explanation for acquired Long QT syndrome by antiparkinsonian drug budipine. Naunyn Schmiedebergs Arch Pharmacol 2003; 368:404-14
22. Mitcheson JS. Drug binding to HERG channels: Evidence for a "non-aromatic" binding site for fluvoxamine. Br J Pharmacol 2003; 139:883-4
23. Valenzuela C, Delpon E, Tamkun MM, Tamargo J, Snyders DJ: Stereoselective block of a human cardiac potassium channel (Kv1.5) by bupivacaine enantiomers. Biophys J 1995; 69:418-27
24. Hamill OP, Marty A, Neher E, Sakmann B, Sigworth FJ: Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflugers Arch 1981; 391:85-100
25. Smith PL, Baukrowitz T, Yellen G: The inward rectification mechanism of the HERG cardiac potassium channel. Nature 1996; 379:833-6
26. Hancox JC, Levi AJ, Witchel HJ: Time course and voltage dependence of expressed HERG current compared with native "rapid" delayed rectifier K current during the cardiac ventricular action potential. Pflugers Arch 1998; 436: 843-53
27. Zhou Z, Gong Q, Ye B, Fan Z, Makielski JC, Robertson GA, January CT: Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature. Biophys J 1998; 74:230-41
28. Sesti F, Abbott GW, Wei J, Murray KT, Saksena S, Schwartz PJ, Priori SG, Roden DM, George Jr, AL Goldstein SA: A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proc Natl Acad Sci U S A 2000; 97:10613-8
29. Wang S, Morales MJ, Liu S, Strauss HC, Rasmusson RL: Modulation of HERG affinity for E-4031 by [K+]o and C-type inactivation. FEBS Lett 1997; 417:43-7
30. Numaguchi H, Mullins FM, Johnson Jr JP Johns, DC, Po SS, Yang IC, Tomaselli GF, Balser JR: Probing the interaction between inactivation gating and Dd-sotalol block of HERG. Circ Res 2000; 87:1012-8
31. Friederich P, Urban BW: Interaction of intravenous anesthetics with human neuronal potassium currents in relation to clinical concentrations. ANESTHESIOLOGY 1999; 91:1853-60
32. Friederich P, Benzenberg D, Trellakis S, Urban BW: Interaction of volatile anesthetics with human Kv channels in relation to clinical concentrations. ANESTHESIOLOGY 2001; 95:954-8
33. Franqueza L, Longobardo M, Vicente J, Delpon E, Tamkun MM, Tamargo J, Snyders DJ, Valenzuela C: Molecular determinants of stereoselective bupivacaine block of hKv1.5 channels. Circ Res 1997; 81:1053-64
34. Albright GA: Cardiac arrest following regional anesthesia with etidocaine or bupivacaine. ANESTHESIOLOGY 1979; 51:285-7
35. Polley LS, Santos AC: Cardiac arrest following regional anesthesia with ropivacaine: Here we go again! ANESTHESIOLOGY 2003; 99:1253-4
36. Webster R, Leishman D, Walker D: Towards a drug concentration effect relationship for QT prolongation and torsades de pointes. Curr Opin Drug Discov Dev 2002; 5:116-26